Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05067231
Other study ID # IRB - 300007834
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2022
Est. completion date January 1, 2026

Study information

Verified date March 2024
Source University of Alabama at Birmingham
Contact Nehal Vekariya, MS
Phone 205-934-7173
Email nvekariya@uabmc.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The UAB Cardiovascular Research Biobank (CARBON) will be a resource that contains biological materials, such as DNA samples, in addition to health and personal information on a large number of people over time. It will be set up so that it can be used in the future as a resource for researchers undertaking a wide range of medical research.


Description:

The UAB Cardiovascular Research Biobank (CARBON) will be a resource that contains pertinent genetic, health, and biological samples such as blood derived from a large-scale population. Researchers may use disease correlates and predictors identified from the genetic, health, and personal information contained in the Biobank as a resource to investigate cardiovascular disease, hypertension, diabetes, and a myriad of other disorders. Through these studies, researchers may identify the progression of risk factors in certain diseases and help develop novel strategies to detect, treat, or prevent such diseases. In addition, the Biobank serves as a valuable tool to assess how certain treatments may respond differently to individuals as a result of genotypic differences. The investigators have demonstrated that lower natriuretic peptide (NP) levels are associated with a decreased insulin sensitivity and have a causal role in the development of diabetes and have also shown that certain populations, such as African Americans, have relatively low NP levels, which may contribute to their underlying risk for insulin resistance. Since NPs play an important role in the regulation of insulin sensitivity, one can infer that relatively low NP levels are an important biological contributor to the high prevalence rates of cardiometabolic disease in African Americans. The Biobank will contain genetic information concerning the presence of gene variants that encode NPs.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date January 1, 2026
Est. primary completion date January 1, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age more than or equal to 18 Exclusion Criteria: - Age <18, at screening - Employees or students associated with the Division of Cardiovascular Disease at UAB will not be recruited due to their vulnerable status and susceptibility to coercion. - Women who are pregnant or who can become pregnant and not practicing an acceptable method of birth control.

Study Design


Locations

Country Name City State
United States University of Alabama at Birmingham Birmingham Alabama

Sponsors (1)

Lead Sponsor Collaborator
University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

References & Publications (1)

Bajaj NS, Gutierrez OM, Arora G, Judd SE, Patel N, Bennett A, Prabhu SD, Howard G, Howard VJ, Cushman M, Arora P. Racial Differences in Plasma Levels of N-Terminal Pro-B-Type Natriuretic Peptide and Outcomes: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. JAMA Cardiol. 2018 Jan 1;3(1):11-17. doi: 10.1001/jamacardio.2017.4207. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Genetic Variants in the NPPA and NPPB gene of the Natriuretic Peptide family associated with the Cardiovascular and Metabolic Diseases Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2